In a phase II trial with COPD patients (616 patients, mean 63 years, 438 males, FEV1% 47.8), treatment with 50 mg MK-7123 (CXCR2 inhibitor) versus placebo results in significant improvement in FEV1 in COPD patients, suggesting clinically important anti-inflammatory effects with CXCR2 antagonism, although dose-related discontinuations were observed because of absolute neutrophil number decreases with MK-7123 (30). Here, CXCR2 is linked to chronic obstructive pulmonary disease.